Krystal Biotech (KRYS) Competitors

Krystal Biotech (NASDAQ:KRYS) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations, community ranking and risk.

Is KRYS or GMAB more profitable?

Genmab A/S has a net margin of 23.49% compared to Krystal Biotech's net margin of 21.68%. Genmab A/S's return on equity of 14.64% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	21.68%	7.54%	6.97%
Genmab A/S	23.49%	14.64%	12.37%

Do institutionals & insiders hold more shares of KRYS or GMAB?

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 14.1% of Krystal Biotech shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate KRYS or GMAB?

Krystal Biotech presently has a consensus price target of $206.67, suggesting a potential upside of 39.27%. Genmab A/S has a consensus price target of $45.20, suggesting a potential upside of 117.31%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community favor KRYS or GMAB?

Krystal Biotech received 129 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 67.44% of users gave Krystal Biotech an outperform vote while only 62.65% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Krystal Biotech	Outperform Votes 290 67.44%	Underperform Votes 140 32.56%
Genmab A/S	Outperform Votes 161 62.65%	Underperform Votes 96 37.35%

Which has preferable earnings & valuation, KRYS or GMAB?

Genmab A/S has higher revenue and earnings than Krystal Biotech. Genmab A/S is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$50.70M	84.18	$10.93M	$1.77	83.84
Genmab A/S	$19.84B	0.69	$631.91M	$1.03	20.19

Does the media prefer KRYS or GMAB?

In the previous week, Genmab A/S had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 7 mentions for Genmab A/S and 4 mentions for Krystal Biotech. Genmab A/S's average media sentiment score of 0.96 beat Krystal Biotech's score of 0.57 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, KRYS or GMAB?

Krystal Biotech has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Summary

Krystal Biotech and Genmab A/S tied by winning 9 of the 18 factors compared between the two stocks.